2025
Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population
Arun A, Liarakos D, Mendiratta G, Kim J, Goshua G, Olson P, Stites E. Integrating epidemiology and genomics data to estimate the prevalence of acquired cysteine drug targets in the U.S. cancer patient population. The Pharmacogenomics Journal 2025, 25: 5. PMID: 40044654, DOI: 10.1038/s41397-025-00364-3.Peer-Reviewed Original ResearchConceptsGenomic dataEstimates of mutation ratesSomatic missense mutationsGenomic informationPopulation-level estimatesCancer patient populationMissense mutationsNon-epidemiologicallyCancer patientsMutation ratePathogenic mutationsCysteine residuesCancer epidemiologyMutation-specificMutation abundanceDrug targetsMutationsIntegrates epidemiologyAbundancePatient populationEpidemiologyGenomePopulationTargeted therapyResidues
2014
Abstract PR04: Cooperation between Ras network mutations in cancer
Stites E, Trampont P, Haney L, Walk S, Ravichandran K. Abstract PR04: Cooperation between Ras network mutations in cancer. Molecular Cancer Research 2014, 12: pr04-pr04. DOI: 10.1158/1557-3125.rasonc14-pr04.Peer-Reviewed Original ResearchRas signaling networkSignaling networksGenomic dataRAS pathway mutationsRas mutantsNetwork mutationGenomic data setsCancer Cell Line EncyclopediaCancer genome sequencingPathway mutationsTumor suppressor gene NF1Wild-type cellsCancer genomic dataGenome sequenceTumor suppressor gene mutationsCancer Genome AtlasGene NF1Cell-based experimentsDisplay synergyMutational pathwaysRAS networkRas oncogeneCo-occurrenceMutationsRas
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply